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Abstract. T h e product of a hybrid cell clone, P3W80, obtained as ascites fluid from mouse
per i toneal cavity had high titres of antihuman chorionic gonadotropin antibodies e.g. 30 to
40% b i n d i n g of 125Ihuman chorionic gonadotropin at 107dilution in a radioimmunoassay. The
antiserum S B 6 (raised against  ßhuman chorionic gonadotropin distributed by National
Institutes of Health, USA gave similar binding at 5000 dilution in parallel runs. The
monoclonal antibody recognized best human chorionic gonadotropin (0.3 mIU of hormone/tube
with B/Bo <75%), but also bound ß and α subunits of human chorionic gonadotropin, 12 and 800
folds lower than human chorionic gonadotropin respectively. No binding was observed with
car boxy terminal peptides of βhuman chorionic gonadotropin ranging from 93 to 145 amino
acid res idues , indicating the lack of recognition of the Cterminal region. No crossreaction
with h u m a n leutinizing hormone was obtained at the physiological surge levels, a significant
compet i t ion (B/B0 <75%, obtainable only at 60 mIU of LER 960 human leutinizing hormone/
tube. T h e antibody had heavy chain of IgG1 and light chain of kappa type. It neutralized the
bioactivity of human chorionic gonadotropin both in vitro and in vivo.
Keywords. Human chorionic gonadotropin; monoclonal antihCG antibody; radioimmuno
assay ; biological neutralization.
Inroduction
itukaitis et al. (1972) obtained an antiserum by immunization of rabbits with beta
unit of h u m a n chorionic gonadotropin (ß-hCG) which had a high specificity for
man c h o r i o n i c  gonadotropin (hCG) and permitted the estimation of this
mone in t h e presence of levels of hLH encountered in the serum. This anti-
um, SB6 h a s served as a valuable reagent for the estimation of hormone levels
1  for r e s e a r c h  on  the hormone function (Goldstein et al., 1974; Braunstein et al.,
6). S u b s e q u e n t l y anti-sera were raised against synthetic carboxy-terminal
tides of ß - h C G  which were totally devoid of cross-reaction with human
inizing h o r m o n e (hLH) (Chen et al., 1976; Ramakrishnan et al., 1979).
vever, d u e to low association constant of the antibodies for hCG, the sensitivity
Abbreviations u s e d : hCG;  human chorionic gonadotropin; ß hCG, β subunit of hCG; hLH, human
nizing h o r m o n e ; hPRL, human prolactin; RIA, radioimmunoassay.
105
106 An anti-hCG clone—properties
of their assay was one order lower for radioimmunoassay of HCG than SB6 (Chen et
al., 1980). The anti-carboxy terminal peptides of ßhCG sera also failed to neutra-
lize the bio-activity of hCG in vivo (Louvet et al., 1974; Matsuura et al., 1976).
We describe here the properties of a monoclonal antibody derived by hybridiza-
tion of mouse myeloma cells with splenocytes obtained from mice immunized with
highly purified hCG. This antibody resembles SB6 in several of its characteristics
and is obtainable in very high titres and unlimited amount. In contrast to the
antibodies raised against carboxy terminal peptides of ßhCG, it neutralizes the bio-
activity of hCG in vivo. This antibody, though highly specific for hCG does not
bind with carboxy terminal peptides of ßhCG, which is suggestive of the
presence within the core of hCG οf epitopes unique to the hormone in immune
reactivity.
Materials and methods
Hormones and peptides
Human chorionic gonadotropin (hCG; 10,000 IU/mg) was made available by Dr.
Tsong of the Population Council, New York, USA. Human luteinizing hormone
(hLH; LER 960) was a generous gift from National Institutes of Health, Bethesda,
Maryland, USA. Human prolactin (hPRL) was supplied by WHO under Quality
Control Programme, βsubunit of hCG (CR119) and αsubunit (CR119) were
made available by Drs S. Birken and R. E. Canfield of Columbia University, New
York, USA. Carboxyterminal peptides of ß-hCG; 93-145; 111-145 and 115-145
conforming to the sequence proposed by Morgan et al. (1975), were prepared by
Dr. Karl Folkers of Texas University and made available through the International
Committee for Contraception Research (ICCR) of the Population Council, New
York, USA. Alkaline phosphatase-tagged goat anti-mouse µ, G1, G2 α, G2b G3, Κ
and λ chainspecific antibodies were obtained from Dr John Kearney, University of
Alabama in Birmingham, Birmingham, Alabama, USA.
Borate buffered saline This was prepared by dissolving 6.185 g of boric acid, 9.54
g of sodium borate and 4.385 g of sodium chloride in 1 litre of double distilled
water.
Alkaline phosphatase substrate buffer It was prepared by dissolving 2.45 mg
MgCl2 in 40 ml of distilled water containing 4.8 ml of diethanolamine (Sigma
Chemicals, St. Louis, Missouri, USA). The pH of the solution was adjusted to 9.8
with 5N HCl and the volume made up to 50 ml with distilled water, p Aminophenyl
phosphate (Biochemical Unit, V. P. Chest Institute, Delhi, India) was dissolved in
the ethanolamine buffer (1 mg/ml) fresh before use.
Monoclonal antibodies
Hybridomas were prepared by fusion of spleen cells obtained from hCG
immunized mice with P3NSI/lAg4l (NSI) a nonsecreting variant of P3X63Ag8
(cell line of Balb/c origin derived from MOPC21) as described elsewhere (Gupta
and Talwar, 1980); Hybrids positive for antihCG antibodies were cloned by
limiting dilution technique. Out of 110 clones thus developed, 10 were studied for
their binding to iodinated gonadotropins as described elsewhere (Gupta and
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Talwar, 1980). One of the positive clones, namely, P3W80 was grown in the intra
peritoneal cavity of the Pristane (Aldrich Chemical Co., Milwaukee, Wisconsin,
USP) primed Balb/c mouse as ascites (Gupta and Talwar, 1980). Ascites fluid
taped from intraperitoneal cavity was made cellfree by centrifugation at 800g for
15 min at 4°C Subsequently, it was heatinactivated at 56°C for 30 min, centrifuged
at 15,000 g to remove debris, diluted with an equal volume of 10 mM phosphate
buffer, pH 7.4 and lyophilized in aliquots of 0.5 ml. It was reconstituted in distilled
water and subsequent dilutions were made in 10 mM phosphate buffer pH 7.4
containing 0.1% sodium azide and 0.1% bovine serum albumin for radioimmuno
assay. For biological neutralization studies, the dilutions were made in isotonic
saline containing 0.1% bovine serum albumin.
Specificity Studies: The reactivity of the ascites fluid obtained from P3W80 clone
of hybrid cells with various hormones was determined by competitive immuno
assay. Iodination of hCG with carrierfree Na125I (Radio chemical Centre,
Amersham, UK) was carried out by the method of Greenwood et al. (1963) as
adopted by Vaitukaitis et al. (1972). The assay system contained 20 µl normal horse
serum, 50 µl 125IhCG (100 to 150 pg), 50 µI solution of different hormones at varying
concentrations and 50 µl of SB6 or P3W80 ascites fluid at the appropriate dilution to
give 30 to 40% binding in absence of competition. Incubation of the assay mixture
was carried out directly at 4°C for 18 to 20 h. The bound and free labelled
hormone was separated by the addition of 1.0 ml of ammonium acetatealcohol
mixture as described by Salahuddin et al., 1976.
Neutralization of biological activity of hCG
The mouse Lyedig cell bioassay system was used to investigate the ability of ascites
fluid to neutralize the biological activity of hCG in vitro. To precipitate immuno
globulins, 0.2 ml of 30% polyethylene glycol solution was added to an equal volume
of ascites fluid, vortexed and incubated overnight at 4°C. It was centrifuged at
1500 g for 15 min, supernatant discarded and the pellet was dissolved in 0.2 ml of
phosphate buffer (pH 7.4). hCG (384 µIU) in 0.1 ml of phosphate buffer (pH 7.4)
was preincubated with increasing dilutions of the precipitated immunoglobulins
for 2 h at 37°C and subsequently at 4°C for 18 h. Leydig cell suspension was
added to the preincubated hormone and the inhibition in the production of testo
sterone in presence of antibodies was estimated (Das et al., 1978). The mono
clonal antibodies were also tested for neutralization of the bioactivity of hCG in
vivo by the mouse uterine weight gain assay. Prepubertal female mice of Balb/c
strain, 2021 days were given subcutaneously a total dose of 0.5 IU of hCG dissolved
in 0.3 ml of isotonic saline with 0.1 % bovine serum albumin in three equally divided
daily doses. Ascites fluid (0.1 ml) at the indicated dilutions was also given sub
cutaneously every day in test mice at a site different from hCG.
Characterization of heavy and light chains of antibody secreted by P 3 W 8 0 clone
Alkaline phosphatase tagged goat antimouse µ, G1, G 2 a , G2b, G3, k and λ chain
specific antibodies were used in solid phase immunoassay to detect the chain
specificity of the monoclonal antibodies. Essentially, the methodology described
by Kerney et al. (1979) was followed except that polyvinyl microelisa plate (96 wells)
were coated with 100 µl of hCG solution (100 µg/ml in distilled water). At the end
of the assay the reaction product of the wells were diluted with 0.3 ml of borate
buffered saline and absorption of the reaction product was measured at 440nm
using a PyeUnicam Spectrophotometer SP8100.
Results
Reactivity of monoclonal antibodies with hCG and its comparision with SB
The mouse ascites fluid containing the product of P3W80 clone had a binding
capacity of 30 to 40% of 125IhCG at a dilution of 107 in RIA. Using the same assay
system, SB6 gave 3040% binding at 5000 dilution. hCG competed well with
labelled hCG for binding to monoclonal antibody tested at 107 dilution (figure 1).
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Figure 2. Radioactivity of monoclonal anti-hCG antibody (P3W80) ascites fluid and SB6 with
alpha and beta subunits of hCG and three carboxy terminal peptides of ß-hCG of 93-145, 111-
145 and 115-145 amino acid.
ß-hCG(SB6), ;α-hCG(SB6), ;carboxy terminal peptides (SB6), (O);ß-hCG (P3W80), ;
αhCG (P3W80); ; carboxys terminal peptides (P3W80),
Competitive binding displacement by hCG of 125IhCG binding to SB6 and P3W80 ascites fluid
was studied. Slope was calculated by the Linear Regression formula Y=mx+C where
Y=LogB/B0(B:cpm bound in the presence of
 125IhCG and unlabelled hCG; B0: cpm bound in
the presence of 125IhCG alone) m=slope, x=Iog hormone cone, and C=intercept.
is the amount of hCG (mlU/tube) required for B/B0=0.5.
hCG standards were prepared in 0.05 Μ phosphate buffer, pH 7.4 containing 0.1% bovine
serum albumin and 0.1% sodiumazide; undiluted urine and serum (diluted 1:10 in phosphate
buffer) obtained from a healthy male.
Table 1. Comparison of radioimmunoassay characteristics of SB6 and the product of the
clone P3W80
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showed a similar reactivity. None of the carboxy terminal peptides of ßhCG (93-
145,111-145,115-145) competed with 125I-hCG for binding sites to this monoclonal or
SB6 (figure 2). However, SB6 at lower dilution (1:100) was shown to bind iodinated
carboxy terminal peptides (93-145) which was not the case with monoclonale even
when tested at 1:100 dilution (unpublished data). The slope of inhibition of SB6
with ß-hCG was also different from those of monoclonal (figure 2).
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hLH at the maximum surge level (Shelly et al, 1973) concentration of 1.2 ng (5.04
mIU/tube) per assay tube did not compete for binding of labelled hCG with mono-
clonal. 60 mlU of hLH/tube was required to obtain a significant cross-reaction in
this assay system (B/Bo =70%) with monoclonals; the amount of hLH producing
similar inhibition was 45 mlU with SB6 (figure 1). The cross-reactivity of the anti-
body with hLH in the Leydig cell bioassay system is given in table 2. PRL was
devoid of cross-reaction with monoclonal and SB6 upto 10 m I U / m l tested. Due to
non-availability of highly purified hFSH and hTSH (free of hLH), the cross-reaction
of monoclonals with these hormones has not been tested.
Table 2. Effect of P3W8O antibody on hCG/hLH induced steroidogenesis by Leydig cell
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by various dilutions of ascites fluid in Leydig cell assay system. At 25,000 dilution,
the asc i tes fluid neutralized the entire hCG (384 µIU) taken for the assay: 50% of
the h o r m o n e was neutralizable at 8×105 dilution.
In the m o u s e uterine weight gain assay, immature mice injected with 0.5 IU of
hCG a l o n e showed about three fold increase (5.5 to 15.5 mg) in the wet weight of
the u te rus as compared to saline injected group. Ascites fluid (upto 1:1000
dilution) g i v e n with same quantity of hCG inhibited completely the hormone-
induced i n c r e a s e of uterine weight (figure 4).
Figure 4. Effect of monoclonal anti-hCG antibody (P3W80) ascites fluid on hCG induced
increase in mouse uterine weight. The bars represent mean values of 6 animals + S.E.
Characterization of heavy and light chains of the monoclonal antibody (P3W80)
The c u l t u r e fluid of the clone P3W80 as well as the ascites fluid developed in the
mouse p e r i t o n e a l cavity was tested for the light and heavy chain classes.
Monospeci f ic antisera against mouse µ, G1 G2 a, G 2 b , G3, k and λ chains were
utilized. The reactivity was assayed by enzyme linked immunoassay. The
Table 3. E n z y m e linked assay for light and heavy chains in the product of the clone P3W80
The a s s a y was carried out as described in Methods.
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product of the P3W80 clone in culture or from ascites fluid reacted only with anti-
mouse G1 and kappa serum as evidenced by absorbance at 440 nm which is shown
in table 3. Other wells showed negligible absorbance. Culture fluid obtained
from myeloma cells (NSI) gave negligible absorbance with all the tested antisera.
Discussion
The antibody made by P3W80 clone is an IgG1, k type; it can bind the complement
and can bring about the antibody induced lysis of cells bearing hCG. This may be
an interesting trait, as anti-hCG antibodies have been observed to exercise a
complement-dependent cytotoxic action against choriocarcinoma cells in vitro
(Currie, 1967; Talwar, 1980).
The antibodies are of neutralizing type. The antibodies abrogate the bio-
activity of hCG both in vitro and in vivo. It may be recalled that antibodies
generated against carboxy terminal peptides unique to ß-hCG fail to intercept the
hCG action in vivo (Louvet et al., 1974; Matsuura et al., 1976). This may be partly
due to the fact that antibodies generated by carboxy terminal peptides are
comparatively of low affinity with Kα of 1.2×109 L/M (Chen et al., 1980). It is,
however, also possible that the epitopes against which the antibodies are directed
has importance. The antibodies against carboxy terminal peptides read sequences
located in a tetrapeptide and a dipeptide sequence, whereas the antibodies
produced by this clone bind to other epitopes or conformation in the hCG/ß-hCG
molecules. These antibodies are devoid of recognition of carboxy terminal
peptides of hCG. Leydig cell receptors do not respond to these peptides and the
determinant(s) inducing biological effect of the hormone reside in core part of ß-
hCG and still better in the associated hCG molecule (Ramakrishnan et al., 1978).
Thus the binding characteristics of the monoclonal antibodies are of interest and
amenable to applications. Preliminary studies in our laboratory demonstrate the
ability of these antibodies to terminate pregnancy in mouse.
These antibodies just as other hybrid cell clone products can be obtained at
extremely high titres. The present antibody binds 30 to 40% of 125I-hCG at 107
dilution. The supply of these antibodies is abundant and theoretically unlimited.
These can be used for radioimmunoassays and enzyme linked assays; the
specificity is very similar to SB6. These antibodies can also be used for neutraliza-
tion of the bioactivity of hCG.
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